Protagenic Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.151; its P/E ratio is -1.12; Protagenic Therapeutics is scheduled to report earnings on April 1, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	$ 322.04K	$ 0.00
Gross Profit	-	-	-	$ 322.04K	-
EBIT	$ -1.36M	$ -1.18M	$ -739.29K	$ -283.52K	$ -893.35K
EBITDA	$ -1.34M	$ -1.15M	$ -714.30K	$ -258.04K	$ -893.35K
Net Income Common Stockholders	$ -1.40M	$ -1.21M	$ 808.17K	$ -662.61K	$ -925.30K
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 5.27M	$ 6.04M	$ 7.65M	$ 7.98M	$ 8.15M
Total Assets	$ 5.43M	$ 6.92M	$ 7.67M	$ 8.04M	$ 8.25M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 344.23K	$ 318.78K
Net Debt	$ -5.27M	$ -6.04M	$ -7.65M	$ -7.63M	$ -7.83M
Total Liabilities	$ 1.28M	$ 1.51M	$ 1.25M	$ 1.12M	$ 872.26K
Stockholders Equity	$ 4.15M	$ 5.41M	$ 6.41M	$ 6.92M	$ 7.38M
Cash Flow	-
Free Cash Flow	$ -711.57K	$ -1.53M	$ -371.83K	$ -182.74K	$ -535.23K
Operating Cash Flow	$ -655.77K	$ -1.53M	$ -371.83K	$ -180.94K	$ -535.23K
Investing Cash Flow	$ 590.72K	$ 1.61M	$ 294.67K	$ 161.77K	$ 357.53K
Financing Cash Flow	-	-	-	-	$ 0.00

Currency in USD

Protagenic Therapeutics Earnings and Revenue History

Income Statement >

Protagenic Therapeutics Debt to Assets

Balance Sheet >

Protagenic Therapeutics Cash Flow

Cash Flow >

Protagenic Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing